Literature DB >> 16189506

First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients.

L S Pilowsky, R A Bressan, J M Stone, K Erlandsson, R S Mulligan, J H Krystal, P J Ell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16189506     DOI： 10.1038/sj.mp.4001751

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN： 1359-4184            Impact factor:   15.992


× No keyword cloud information.
  90 in total

Review 1.  Excitation, inhibition, local oscillations, or large-scale loops: what causes the symptoms of schizophrenia?

Authors:  John Lisman
Journal:  Curr Opin Neurobiol       Date:  2011-11-11       Impact factor: 6.627

2.  Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.

Authors:  Surendra P Singh; Vidhi Singh
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

Review 3.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

4.  ErbB4 is a suppressor of long-term potentiation in the adult hippocampus.

Authors:  Graham M Pitcher; Simon Beggs; Ran-Sook Woo; Lin Mei; Michael W Salter
Journal:  Neuroreport       Date:  2008-01-22       Impact factor: 1.837

Review 5.  Region-specific changes in gamma and beta2 rhythms in NMDA receptor dysfunction models of schizophrenia.

Authors:  Anita K Roopun; Mark O Cunningham; Claudia Racca; Kai Alter; Roger D Traub; Miles A Whittington
Journal:  Schizophr Bull       Date:  2008-06-09       Impact factor: 9.306

6.  Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia.

Authors:  Colm M P O'Tuathaigh; Brian P Kirby; Paula M Moran; John L Waddington
Journal:  Schizophr Bull       Date:  2009-11-24       Impact factor: 9.306

7.  Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T.

Authors:  Juan R Bustillo; Hongji Chen; Thomas Jones; Nicholas Lemke; Christopher Abbott; Clifford Qualls; Jose Canive; Charles Gasparovic
Journal:  JAMA Psychiatry       Date:  2014-03       Impact factor: 21.596

Review 8.  Peripheral biomarkers revisited: integrative profiling of peripheral samples for psychiatric research.

Authors:  Akiko Hayashi-Takagi; Marquis P Vawter; Kazuya Iwamoto
Journal:  Biol Psychiatry       Date:  2013-10-18       Impact factor: 13.382

9.  NMDA receptor phosphorylation at a site affected in schizophrenia controls synaptic and behavioral plasticity.

Authors:  Bo Li; Nino Devidze; Denis Barengolts; Naseem Prostak; Eleana Sphicas; Alfonso J Apicella; Roberto Malinow; Effat S Emamian
Journal:  J Neurosci       Date:  2009-09-23       Impact factor: 6.167

10.  Disrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1.

Authors:  Akiko Hayashi-Takagi; Manabu Takaki; Nick Graziane; Saurav Seshadri; Hannah Murdoch; Allan J Dunlop; Yuichi Makino; Anupamaa J Seshadri; Koko Ishizuka; Deepak P Srivastava; Zhong Xie; Jay M Baraban; Miles D Houslay; Toshifumi Tomoda; Nicholas J Brandon; Atsushi Kamiya; Zhen Yan; Peter Penzes; Akira Sawa
Journal:  Nat Neurosci       Date:  2010-02-07       Impact factor: 24.884
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.